close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

8.65 -9.42

Strong Buy

Prijsupdate 23 apr 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.65

Max

9.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-69M

-102M

Verkoop

-10M

34M

EPS

-5.69

Winstmarge

-299.886

Werknemers

228

EBITDA

4.7M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+57.07% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

44M

202M

Vorige openingsprijs

18.07

Vorige sluitingsprijs

8.65

Nieuwssentiment

By Acuity

50%

50%

178 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

DJ

Lezen

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

DJ

Lezen

23 apr 2026, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

DJ

Lezen

23 apr 2026, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

23 apr 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

23 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

DJ

Lezen

23 apr 2026, 23:13 UTC

Acquisities, Fusies, Overnames

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

DJ

Lezen

23 apr 2026, 22:33 UTC

Winsten

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

DJ

Lezen

23 apr 2026, 22:17 UTC

Winsten

PLS Executed Offtake Agreement With Ronbay

DJ

Lezen

23 apr 2026, 22:17 UTC

Winsten

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

DJ

Lezen

23 apr 2026, 22:16 UTC

Winsten

PLS Commences Commissioning of Midstream Demonstration Plant

DJ

Lezen

23 apr 2026, 22:15 UTC

Winsten

PLS Group Reaffirms FY26 Guidance for All Metrics

DJ

Lezen

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Margin From Operations A$461M at March 31

DJ

Lezen

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

DJ

Lezen

23 apr 2026, 22:13 UTC

Winsten

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

DJ

Lezen

23 apr 2026, 22:12 UTC

Winsten

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

DJ

Lezen

23 apr 2026, 22:12 UTC

Winsten

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

DJ

Lezen

23 apr 2026, 22:11 UTC

Winsten

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

DJ

Lezen

23 apr 2026, 22:10 UTC

Winsten

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

DJ

Lezen

23 apr 2026, 22:09 UTC

Winsten

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

DJ

Lezen

23 apr 2026, 22:08 UTC

Winsten

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

DJ

Lezen

23 apr 2026, 22:04 UTC

Winsten

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

DJ

Lezen

23 apr 2026, 21:56 UTC

Marktinformatie
Winsten

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

DJ

Lezen

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

DJ

Lezen

23 apr 2026, 21:27 UTC

Winsten

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

DJ

Lezen

23 apr 2026, 21:25 UTC

Winsten

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

DJ

Lezen

23 apr 2026, 21:24 UTC

Winsten

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

DJ

Lezen

23 apr 2026, 21:24 UTC

Winsten

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

DJ

Lezen

23 apr 2026, 21:21 UTC

Winsten

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

DJ

Lezen

23 apr 2026, 21:21 UTC

Winsten

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

57.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15 USD  57.07%

Hoogste 28 USD

Laagste 8 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

178 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

JNJ

Johnson and Johnson

230.63

↑ +2.12%

ABT

Abbott Laboratories

92.43

↑ +0.79%

MDT

Medtronic PLC

83.72

↑ +0.54%

A

Agilent Technologies Inc

114.27

↓-5.32%

VEEV

Veeva Systems Inc

156.08

↓-4.6%
help-icon Live chat